Search Results - "Deeg, H. Joachim"

How I treat refractory acute GVHD by Deeg, H. Joachim

“…Graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) is associated with considerable morbidity and mortality,…”
Get full text

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts by McDonald, George B, Sandmaier, Brenda M, Mielcarek, Marco, Sorror, Mohamed, Pergam, Steven A, Cheng, Guang-Shing, Hingorani, Sangeeta, Boeckh, Michael, Flowers, Mary D, Lee, Stephanie J, Appelbaum, Frederick R, Storb, Rainer, Martin, Paul J, Deeg, H Joachim, Schoch, Gary, Gooley, Ted A

“…Allogeneic hematopoietic cell transplantation is indicated for refractory hematologic cancer and some nonmalignant disorders. Survival is limited by recurrent…”
Get full text

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes by Scott, Bart L, Pasquini, Marcelo C, Logan, Brent R, Wu, Juan, Devine, Steven M, Porter, David L, Maziarz, Richard T, Warlick, Erica D, Fernandez, Hugo F, Alyea, Edwin P, Hamadani, Mehdi, Bashey, Asad, Giralt, Sergio, Geller, Nancy L, Leifer, Eric, Le-Rademacher, Jennifer, Mendizabal, Adam M, Horowitz, Mary M, Deeg, H Joachim, Horwitz, Mitchell E

“…Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related…”
Get full text

Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53 -Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes by Mishra, Asmita, Tamari, Roni, DeZern, Amy E, Byrne, Michael T, Gooptu, Mahasweta, Chen, Yi-Bin, Deeg, H Joachim, Sallman, David, Gallacher, Phillip, Wennborg, Anders, Hickman, Denice K, Attar, Eyal C, Fernandez, Hugo F

“…Outcomes are poor in -mutant (m ) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant…”
Get full text

Chimerism, the Microenvironment and Control of Leukemia by Deeg, H Joachim

“…Transplantation of allogeneic hematopoietic cells faces two barriers: failure of engraftment due to a host versus graft reaction, and the attack of donor cells…”
Get full text

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation by Baker, K. Scott, Leisenring, Wendy M., Goodman, Pamela J., Ermoian, Ralph P., Flowers, Mary E., Schoch, G., Storb, Rainer, Sandmaier, Brenda M., Deeg, H. Joachim

“…We examined the impact of total body irradiation (TBI) dose and fractionation on risk of subsequent malignant neoplasms (SMNs) in the era of reduced-intensity…”
Get full text

Silver Lining: Reduced Relapse with Chronic GVHD after Transplant for MDS by Eckel, Ashley M, Deeg, H Joachim

“…Chronic GVHD following hematopoietic cell transplantation is associated with reduced relapse incidence in patients with leukemias. This impact has been…”
Get full text

Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review by Holtan, Shernan G., Yu, Jingbo, Choe, Hannah K., Paranagama, Dilan, Tang, Jackson, Naim, Ahmad, Galvin, John, Joachim Deeg, H.

“…Acute graft-versus-host disease (GVHD) remains a barrier to successful allogeneic hematopoietic cell transplantation (HCT) outcomes. This multicenter,…”
Get full text

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party by McLornan, Donal P., Hernandez-Boluda, Juan Carlos, Czerw, Tomasz, Cross, Nicholas, Joachim Deeg, H., Ditschkowski, Marcus, Moonim, Mufaddal T., Polverelli, Nicola, Robin, Marie, Aljurf, Mahmoud, Conneally, Eibhlin, Hayden, Patrick, Yakoub-Agha, Ibrahim

“…Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative approach in myelofibrosis (MF). Despite advances over recent decades,…”
Get full text

SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition by Kim, Eunhee, Ilagan, Janine O., Liang, Yang, Daubner, Gerrit M., Lee, Stanley C.-W., Ramakrishnan, Aravind, Li, Yue, Chung, Young Rock, Micol, Jean-Baptiste, Murphy, Michele E., Cho, Hana, Kim, Min-Kyung, Zebari, Ahmad S., Aumann, Shlomzion, Park, Christopher Y., Buonamici, Silvia, Smith, Peter G., Deeg, H. Joachim, Lobry, Camille, Aifantis, Iannis, Modis, Yorgo, Allain, Frederic H.-T., Halene, Stephanie, Bradley, Robert K., Abdel-Wahab, Omar

“…Mutations affecting spliceosomal proteins are the most common mutations in patients with myelodysplastic syndromes (MDS), but their role in MDS pathogenesis…”
Get full text

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation by Sorror, Mohamed L, Storb, Rainer F, Sandmaier, Brenda M, Maziarz, Richard T, Pulsipher, Michael A, Maris, Michael B, Bhatia, Smita, Ostronoff, Fabiana, Deeg, H Joachim, Syrjala, Karen L, Estey, Elihu, Maloney, David G, Appelbaum, Frederick R, Martin, Paul J, Storer, Barry E

“…Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI)…”
Get full text

Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation by MARTIN, Paul J, COUNTS, George W, STORER, Barry E, APPELBAUM, Frederick R, LEE, Stephanie J, SANDERS, Jean E, JOACHIM DEEG, H, FLOWERS, Mary E. D, SYRJALA, Karen L, HANSEN, John A, STORB, Rainer F

“…PURPOSE Hematopoietic cell transplantation can cure hematologic malignancies and other diseases, but this treatment can also cause late complications. Previous…”
Get full text

Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis by Salit, Rachel B., Scott, Bart L., Stevens, Emily A., Baker, Kelsey K., Gooley, Ted A., Deeg, H. Joachim

“…Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis…”
Get full text

Allogeneic Hematopoietic Cell Transplantation and Other Expensive Cellular Therapies: A Miracle for the Few but Off Limits to Many? by Khera, Nandita, Deeg, H Joachim, Kodish, Eric, Rondelli, Damiano, Majhail, Navneet

Get full text

Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML by Paras, Gabrielle, Morsink, Linde M., Othus, Megan, Milano, Filippo, Sandmaier, Brenda M., Zarling, Lucas C., Palmieri, Raffaele, Schoch, Gary, Davis, Chris, Bleakley, Marie, Flowers, Mary E.D., Deeg, H. Joachim, Appelbaum, Frederick R., Storb, Rainer, Walter, Roland B.

“…In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after allogeneic hematopoietic cell transplantation (HCT) is an established…”
Get full text

A disease risk index for patients undergoing allogeneic stem cell transplantation by Armand, Philippe, Gibson, Christopher J., Cutler, Corey, Ho, Vincent T., Koreth, John, Alyea, Edwin P., Ritz, Jerome, Sorror, Mohamed L., Lee, Stephanie J., Deeg, H. Joachim, Storer, Barry E., Appelbaum, Frederick R., Antin, Joseph H., Soiffer, Robert J., Kim, Haesook T.

“…The outcome of allogeneic HSCT varies considerably by the disease and remission status at the time of transplantation. Any retrospective or prospective HSCT…”
Get full text

Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study by Holtan, Shernan G., Yu, Jingbo, Paranagama, Dilan, Tang, Jackson, Choe, Hannah K., Naim, Ahmad, Joachim Deeg, H., Galvin, John

“…Acute graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). This…”
Get full text

Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML by Morsink, Linde M., Othus, Megan, Bezerra, Evandro D., Wood, Brent L., Fang, Min, Sandmaier, Brenda M., Mielcarek, Marco, Schoch, Gary, Storb, Rainer, Deeg, H. Joachim, Appelbaum, Frederick R., Walter, Roland B.

“…Allogeneic hematopoietic cell transplantation (HCT) is often unsuccessful for monosomal karyotype (MK) acute myeloid leukemia (AML). To what degree failures…”
Get full text

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation by Scott, Bart L., Gooley, Ted A., Sorror, Mohamed L., Rezvani, Andrew R., Linenberger, Michael L., Grim, Jonathan, Sandmaier, Brenda M., Myerson, David, Chauncey, Thomas R., Storb, Rainer, Buxhofer-Ausch, Veronika, Radich, Jerald P., Appelbaum, Frederick R., Deeg, H. Joachim

“…Studies by the International Working Group showed that the prognosis of myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring…”
Get full text

Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation by SORROR, Mohamed L, SANDMAIER, Brenda M, STORER, Barry E, MARIS, Michael B, BARON, Frederic, MALONEY, David G, SCOTT, Bart L, JOACHIM DEEG, H, APPELBAUM, Frederick R, STORB, Rainer

“…Retrospective studies have shown similar survival among patients with acute myeloid leukemia (AML) and myelodysplasia (MDS) after nonmyeloablative compared…”
Get full text